Clinical Trial Detail

NCT ID NCT03261947
Title A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

colon adenocarcinoma

pancreatic adenocarcinoma

rectum adenocarcinoma

lung squamous cell carcinoma

esophagus squamous cell carcinoma

Therapies

TAK-931

Age Groups: adult senior

No variant requirements are available.